专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2023004282A2 IL12 RECEPTOR AGONISTS AND METHODS OF USE THEREOF 审中-公开
公开(公告)号：WO2023004282A2
公开(公告)日：2023-01-26
申请号：PCT/US2022/073832
申请日：2022-07-18
申请人： REGENERON PHARMACEUTICALS, INC.
发明人： CHANG, Aaron , WU, Jiaxi , ZHANG, Tong , BLOCH, Nicolin , ULLMAN, Erica , SMITH, Eric , LIN, Chia-Yang , DAVIS, Samuel
IPC分类号： C07K14/715 , C07K16/24 , A61K38/00 , A61K47/6845 , A61P35/00 , C07K14/5434 , C07K14/7155 , C07K16/244 , C07K16/2833 , C07K16/30 , C07K2317/52 , C07K2317/55 , C07K2317/622 , C07K2317/75 , C07K2319/00 , C07K2319/01 , C07K2319/30
摘要： The present disclosure relates to IL12 receptor agonists with improved therapeutic profiles.

3. 发明申请

WO2018058001A1 ANTI-STEAP2 ANTIBODIES, ANTIBODY-DRUG CONJUGATES, AND BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND STEAP2 AND CD3, AND USES THEREOF 审中-公开
标题翻译：抗STEAP2抗体，抗体药物偶联物和结合STEAP2和CD3的双特异性抗原结合分子及其用途
公开(公告)号：WO2018058001A1
公开(公告)日：2018-03-29
申请号：PCT/US2017/053111
申请日：2017-09-22
申请人： REGENERON PHARMACEUTICALS, INC.
发明人： RUDGE, John , DELFINO, Frank , HABER, Lauric , SMITH, Eric , KIRSHNER, Jessica R. , CRAWFORD, Alison , NITTOLI, Thomas
IPC分类号： C07K16/30 , C07K16/28 , A61K47/68 , A61P35/00
摘要： The protein known as six-transmembrane epithelial antigen of prostate 2 (STEAP2) is highly expressed in prostate cancer and is associated with the expression of other prostate cancer-associated genes. The present invention provides novel full-length human IgG antibodies that bind to human STEAP2 (monospecific antibodies). The present invention also provides novel bispecific antibodies (bsAbs) that bind to both STEAP2 and CD3 and activate T cells via the CD3 complex in the presence of STEAP2 -expressing tumors. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human and monkey CD3, and a second antigen-binding molecule that specifically binds humanSTEAP2. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing STEAP2. The bispecific antigen-binding molecules of the invention are useful for the treatment of prostate diseases and disorders in which an upregulated or induced STEAP2 -targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of prostate cancers, including castrate-resistant prostate cancer. The present invention also includes anti-STEAP2 antibody drug conjugates which inhibit tumor growth in vivo.
摘要翻译：被称为前列腺2（STEAP2）的六跨膜上皮抗原的蛋白质在前列腺癌中高度表达，并与其他前列腺癌相关基因的表达相关。本发明提供了与人STEAP2（单特异性抗体）结合的新型全长人IgG抗体。本发明还提供了新的双特异性抗体（bsAb），其在表达STEAP2的肿瘤存在下通过CD3复合物结合STEAP2和CD3并激活T细胞。根据某些实施方案，本发明提供了包含特异性结合人和猴CD3的第一抗原结合结构域和特异性结合人STEAP2的第二抗原结合分子的双特异性抗原结合分子。在某些实施方案中，本发明的双特异性抗原结合分子能够抑制表达STEAP2的肿瘤的生长。本发明的双特异性抗原结合分子可用于治疗需要上调或诱导的STEAP2靶向的免疫应答和/或治疗有益的前列腺疾病和病症。例如，本发明的双特异性抗体可用于治疗前列腺癌，包括去势抵抗性前列腺癌。本发明还包括抑制体内肿瘤生长的抗STEAP2抗体药物缀合物。

4. 发明申请

WO2010151792A1 READILY ISOLATED BISPECIFIC ANTIBODIES WITH NATIVE IMMUNOGLOBULIN FORMAT 审中-公开
标题翻译：具有本身免疫球蛋白形式的自分离分离抗体
公开(公告)号：WO2010151792A1
公开(公告)日：2010-12-29
申请号：PCT/US2010/040028
申请日：2010-06-25
申请人： REGENERON PHARMACEUTICALS, INC. , DAVIS, Samuel , SMITH, Eric , MACDONALD, Douglas , OLSON, Kara, Louise
发明人： DAVIS, Samuel , SMITH, Eric , MACDONALD, Douglas , OLSON, Kara, Louise
IPC分类号： C07K16/06 , C07K16/46
CPC分类号： C07K1/22 , A61K2039/505 , C07K16/247 , C07K16/248 , C07K16/2809 , C07K16/2866 , C07K16/2887 , C07K16/468 , C07K2317/21 , C07K2317/31 , C07K2317/52 , C07K2317/526 , C07K2317/56 , C07K2317/76
摘要： A bispecific antibody format providing ease of isolation is provided, comprising immunoglobulin heavy chain variable domains that are differentially modified in the CH3 domain, wherein the differential modifications are non-immunogenic or substantially non- immunogenic with respect to the CH3 modifications, and at least one of the modifications results in a differential affinity for the bispecific antibody for an affinity reagent such as Protein A, and the bispecific antibody is isolable from a disrupted cell, from medium, or from a mixture of antibodies based on its affinity for Protein A.
摘要翻译：提供了提供易于分离的双特异性抗体形式，包括在CH3结构域中差异修饰的免疫球蛋白重链可变结构域，其中所述差异修饰是相对于CH3修饰的非免疫原性或基本上不免疫原性的，以及至少一种基于其对蛋白A的亲和力，所述修饰导致针对亲和试剂例如蛋白A的双特异性抗体的差异亲和力，并且双特异性抗体可从破坏的细胞，培养基或抗体混合物中分离。

5. 发明申请

WO2006138610A3 INTERFERON-ALPHA/BETA BINDING FUSION PROTEINS AND THERAPEUTIC USES THEREOF 审中-公开
公开(公告)号：WO2006138610A3
公开(公告)日：2006-12-28
申请号：PCT/US2006/023569
申请日：2006-06-16
申请人： REGENERON PHARMACEUTICALS, INC. , SMITH, Eric , KAROW, Margaret
发明人： SMITH, Eric , KAROW, Margaret
IPC分类号： C12P21/02 , C12P21/04 , C07K14/00 , A61K45/00
摘要： Polypeptides and multimeric polypeptides capable of binding interferon α and/or interferon β which are useful therapeutically in methods of treating interferon α/β related conditions or diseases.

6. 发明申请

WO2004072233A3 HIV-SPECIFIC FUSION PROTEINS AND THERAPEUTIC AND DIAGNOSTIC METHODS FOR USE 审中-公开
公开(公告)号：WO2004072233A3
公开(公告)日：2004-08-26
申请号：PCT/US2004/002650
申请日：2004-01-30
申请人： REGENERON PHARMACEUTICALS, INC. , GLASS, David, J. , KAROW, Margaret , SMITH, Eric
发明人： GLASS, David, J. , KAROW, Margaret , SMITH, Eric
IPC分类号： C12N15/62
摘要： A HIV-specific fusion polypeptide, comprising: (a) one or more domains which comprise a cellular co-receptor protein, or a fragment, derivative, or functional equivalent thereof; (b) one or more domains which comprise a cellular receptor protein, or a fragment, derivative, or functional equivalent thereof; and optionally (c) a multimerizing component; and (d) one or more domains of a viral protein, or a fragment or derivative thereof. In specific embodiments, the HIV-specific fusion protein is a multimer capable of binding an HIV particle, and is useful for the treatment of HIV infections.

7. 发明申请

WO2021127495A1 NOVEL IL2 AGONISTS AND METHODS OF USE THEREOF 审中-公开
公开(公告)号：WO2021127495A1
公开(公告)日：2021-06-24
申请号：PCT/US2020/066096
申请日：2020-12-18
申请人： REGENERON PHARMACEUTICALS, INC.
发明人： WU, Jiaxi , ZHANG, Tong , MOLINA-PORTELA, Maria del Pilar , SMITH, Eric , LIN, Chia-Yang , MEAGHER, Thomas
IPC分类号： C07K16/46 , C07K14/54 , A61P35/00 , A61P37/06 , A61K2039/505 , A61K2039/5156 , A61K2039/585 , A61K35/17 , A61K38/00 , A61K39/0011 , A61K39/12 , A61K39/39 , A61K47/6849 , A61P31/14 , A61P31/20 , C07K14/5443 , C07K14/55 , C07K14/7051 , C07K14/70517 , C07K14/70539 , C07K14/70578 , C07K14/7155 , C07K16/084 , C07K16/2818 , C07K2317/34 , C07K2317/622 , C07K2319/00 , C07K2319/02 , C07K2319/03 , C07K2319/30 , C07K2319/33 , C12N2710/16134 , C12N2710/20034 , C12N2740/13034
摘要： The present disclosure relates to IL2 agonists with improved therapeutic profiles.

8. 发明申请

WO2021026409A1 NOVEL ANTIGEN BINDING MOLECULE FORMATS 审中-公开
公开(公告)号：WO2021026409A1
公开(公告)日：2021-02-11
申请号：PCT/US2020/045309
申请日：2020-08-07
申请人： REGENERON PHARMACEUTICALS, INC.
发明人： ZHANG, Tong , PYLES, Erica , ROSCONI, Michael , LIU, Nina , PATEL, Supriya , SMITH, Eric , MURPHY, Andrew , LIN, Chiayang , DAVIS, Samuel
IPC分类号： C07K16/24 , C07K16/28 , C07K16/46
摘要： Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.

9. 发明申请

WO2020132066A8 BISPECIFIC ANTI-CD28 X ANTI-CD22 ANTIBODIES AND USES THEREOF 审中-公开
公开(公告)号：WO2020132066A8
公开(公告)日：2020-06-25
申请号：PCT/US2019/067173
申请日：2019-12-18
申请人： REGENERON PHARMACEUTICALS, INC.
发明人： MURPHY, Andrew, J. , SKOKOS, Dimitris , WAITE, Janelle , ULLMAN, Erica , HERMANN, Aynur , SMITH, Eric , OLSON, Kara , WEI, Joyce , YANCOPOULOS, George, D.
IPC分类号： A61K39/395 , A61P35/02 , C07K16/28 , C07K16/30
摘要： The present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD28, and a second antigen- binding molecule that specifically binds human CD-22. In certain embodiments, the bispecific antigen- binding molecules of the present invention are capable of inhibiting the growth of tumors expressing CD-22, such as B-cell lymphomas. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an up-regulated or induced targeted immune response is desired and/or therapeutically beneficial.

10. 发明申请

WO2019246514A1 BISPECIFIC ANTI-PSMA X ANTI-CD28 ANTIBODIES AND USES THEREOF 审中-公开
公开(公告)号：WO2019246514A1
公开(公告)日：2019-12-26
申请号：PCT/US2019/038460
申请日：2019-06-21
申请人： REGENERON PHARMACEUTICALS, INC.
发明人： MURPHY, Andrew, J. , SKOKOS, Dimitris , WAITE, Janelle , ULLMAN, Erica , HERMANN, Aynur , SMITH, Eric , HABER, Lauric , YANCOPOULOS, George, D.
IPC分类号： A61P35/00 , C07K16/28 , C07K16/30 , A61K39/00
摘要： The present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD28, and a second antigen-binding molecule that specifically binds human PSMA. In certain embodiments, the bispecific antigen- binding molecules of the present invention are capable of inhibiting the growth of tumors expressing PSMA, such as prostate tumors. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an up-regulated or induced targeted immune response is desired and/or therapeutically beneficial.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式